These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

815 related items for PubMed ID: 23676340

  • 1. Progression of Alzheimer's disease during a three-year follow-up using the CERAD-NB total score: Kuopio ALSOVA study.
    Hallikainen I, Hänninen T, Fraunberg M, Hongisto K, Välimäki T, Hiltunen A, Karppi P, Sivenius J, Soininen H, Koivisto AM, ALSOVA study group.
    Int Psychogeriatr; 2013 Aug; 25(8):1335-44. PubMed ID: 23676340
    [Abstract] [Full Text] [Related]

  • 2. The Progression of Alzheimer's Disease Can Be Assessed with a Short Version of the CERAD Neuropsychological Battery: The Kuopio ALSOVA Study.
    Hallikainen I, Martikainen J, Lin PJ, Cohen JT, Lahoz R, Välimäki T, Hongisto K, Väätäinen S, Vanhanen M, Neumann PJ, Hänninen T, Koivisto AM.
    Dement Geriatr Cogn Dis Extra; 2014 Aug; 4(3):494-508. PubMed ID: 25685140
    [Abstract] [Full Text] [Related]

  • 3. CERAD neuropsychological compound scores are accurate in detecting prodromal alzheimer's disease: a prospective AddNeuroMed study.
    Paajanen T, Hänninen T, Tunnard C, Hallikainen M, Mecocci P, Sobow T, Tsolaki M, Vellas B, Lovestone S, Soininen H.
    J Alzheimers Dis; 2014 Aug; 39(3):679-90. PubMed ID: 24246420
    [Abstract] [Full Text] [Related]

  • 4. Use of Anti-Dementia Drugs in Relation to Change in Cognition, Behavior, and Functioning in Alzheimer's Disease over a Three-Year Period: Kuopio ALSOVA Study.
    Törmälehto SM, Martikainen JA, Väätäinen ST, Hallikainen IT, Hallikainen M, Bell JS, Koivisto AM.
    J Alzheimers Dis; 2015 Aug; 48(4):1033-41. PubMed ID: 26444756
    [Abstract] [Full Text] [Related]

  • 5. Use of psychotropic medications in relation to neuropsychiatric symptoms, cognition and functional performance in Alzheimer's disease over a three-year period: Kuopio ALSOVA study.
    Törmälehto S, Martikainen J, Bell JS, Hallikainen I, Koivisto AM.
    Int Psychogeriatr; 2017 Oct; 29(10):1723-1733. PubMed ID: 28625207
    [Abstract] [Full Text] [Related]

  • 6. Quality of Life in relation to neuropsychiatric symptoms in Alzheimer's disease: 5-year prospective ALSOVA cohort study.
    Hongisto K, Hallikainen I, Selander T, Törmälehto S, Väätäinen S, Martikainen J, Välimäki T, Hartikainen S, Suhonen J, Koivisto AM.
    Int J Geriatr Psychiatry; 2018 Jan; 33(1):47-57. PubMed ID: 28067961
    [Abstract] [Full Text] [Related]

  • 7. Relationships between Cognition and Activities of Daily Living in Alzheimer's Disease During a 5-Year Follow-Up: ALSOVA Study.
    Saari T, Hallikainen I, Hänninen T, Räty H, Koivisto A.
    J Alzheimers Dis; 2018 Jan; 64(1):269-279. PubMed ID: 29889073
    [Abstract] [Full Text] [Related]

  • 8. Trajectories and risk factors of dementia progression: a memory clinic cohort followed up to 3 years from diagnosis.
    Edwin TH, Strand BH, Persson K, Engedal K, Selbæk G, Knapskog AB.
    Int Psychogeriatr; 2021 Aug; 33(8):779-789. PubMed ID: 33213607
    [Abstract] [Full Text] [Related]

  • 9. A total score for the CERAD neuropsychological battery.
    Chandler MJ, Lacritz LH, Hynan LS, Barnard HD, Allen G, Deschner M, Weiner MF, Cullum CM.
    Neurology; 2005 Jul 12; 65(1):102-6. PubMed ID: 16009893
    [Abstract] [Full Text] [Related]

  • 10. CERAD neuropsychological battery total score in multinational mild cognitive impairment and control populations: the AddNeuroMed study.
    Paajanen T, Hänninen T, Tunnard C, Mecocci P, Sobow T, Tsolaki M, Vellas B, Lovestone S, Soininen H, Addneuromed Consortium.
    J Alzheimers Dis; 2010 Jul 12; 22(4):1089-97. PubMed ID: 20930314
    [Abstract] [Full Text] [Related]

  • 11. Longitudinal changes in awareness over 36 months in patients with mild Alzheimer's disease.
    Vogel A, Waldorff FB, Waldemar G.
    Int Psychogeriatr; 2015 Jan 12; 27(1):95-102. PubMed ID: 25075811
    [Abstract] [Full Text] [Related]

  • 12. A 2-year follow-up of 233 very mild (CDR 0.5) Alzheimer's disease patients (REAL.FR cohort).
    Nourhashémi F, Ousset PJ, Gillette-Guyonnet S, Cantet C, Andrieu S, Vellas B, REAL.FR cohort.
    Int J Geriatr Psychiatry; 2008 May 12; 23(5):460-5. PubMed ID: 17894422
    [Abstract] [Full Text] [Related]

  • 13. The CERAD neuropsychological assessment battery total score detects and predicts Alzheimer disease dementia with high diagnostic accuracy.
    Wolfsgruber S, Jessen F, Wiese B, Stein J, Bickel H, Mösch E, Weyerer S, Werle J, Pentzek M, Fuchs A, Köhler M, Bachmann C, Riedel-Heller SG, Scherer M, Maier W, Wagner M, AgeCoDe Study Group.
    Am J Geriatr Psychiatry; 2014 Oct 12; 22(10):1017-28. PubMed ID: 23759289
    [Abstract] [Full Text] [Related]

  • 14. Longitudinal Neuropsychological Outcome in Taiwanese Alzheimer's Disease Patients Treated with Medication.
    Yang YH, Wu MN, Chou PS, Su HC, Lin SH, Sung PS.
    Curr Alzheimer Res; 2018 Mar 14; 15(5):474-481. PubMed ID: 29032750
    [Abstract] [Full Text] [Related]

  • 15. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
    Tariot PN, Cummings JL, Katz IR, Mintzer J, Perdomo CA, Schwam EM, Whalen E.
    J Am Geriatr Soc; 2001 Dec 14; 49(12):1590-9. PubMed ID: 11843990
    [Abstract] [Full Text] [Related]

  • 16. A comparison of the Cohen-Mansfield agitation inventory with the CERAD behavioral rating scale for dementia in community-dwelling persons with Alzheimer's disease.
    Weiner MF, Koss E, Patterson M, Jin S, Teri L, Thomas R, Thal LJ, Whitehouse P.
    J Psychiatr Res; 1998 Dec 14; 32(6):347-51. PubMed ID: 9844950
    [Abstract] [Full Text] [Related]

  • 17. The CERAD Neuropsychologic Battery Total Score and the progression of Alzheimer disease.
    Rossetti HC, Munro Cullum C, Hynan LS, Lacritz LH.
    Alzheimer Dis Assoc Disord; 2010 Dec 14; 24(2):138-42. PubMed ID: 20505431
    [Abstract] [Full Text] [Related]

  • 18. CERAD-neuropsychological battery in screening mild Alzheimer's disease.
    Sotaniemi M, Pulliainen V, Hokkanen L, Pirttilä T, Hallikainen I, Soininen H, Hänninen T.
    Acta Neurol Scand; 2012 Jan 14; 125(1):16-23. PubMed ID: 21198445
    [Abstract] [Full Text] [Related]

  • 19. Specific Neuropsychiatric Symptoms Are Associated with Faster Progression in Alzheimer's Disease: Results of the Prospective Dementia Registry (PRODEM-Austria).
    Defrancesco M, Marksteiner J, Kemmler G, Dal-Bianco P, Ransmayr G, Benke T, Mosbacher J, Höller Y, Schmidt R.
    J Alzheimers Dis; 2020 Jan 14; 73(1):125-133. PubMed ID: 31744004
    [Abstract] [Full Text] [Related]

  • 20. "Noncognitive" symptoms of early Alzheimer disease: a longitudinal analysis.
    Masters MC, Morris JC, Roe CM.
    Neurology; 2015 Feb 10; 84(6):617-22. PubMed ID: 25589671
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.